Elite Pharmaceuticals, Inc.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Elite Pharmaceuticals reports stellar Q1 results and eyes growth opportunities

Elite Pharmaceuticals delivered robust Q1 2025 results, showcasing significant revenue and income growth, improved cash flow, and strong financial health. Strategic investments and operational focus contributed to the company's success.
With a solid cash position, working capital, and proactive growth initiatives, Elite Pharmaceuticals is well-positioned to capitalize on market opportunities, drive innovation, and maintain compliance and operational excellence.
While challenges in sustaining growth and navigating regulatory requirements exist, Elite Pharmaceuticals' focus on strategic planning, financial discipline, and market expansion presents promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elite Pharmaceuticals, Inc. engages in the provision of development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications and New Drug Applications segments. The ANDA segment includes generic pharmaceuticals. The NDA segment is composed of branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.

Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2022 ("Fiscal 2022"). Consolidated revenues for Fiscal 2022 were $32.3 million, an increase of $6.9 million or 27% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information

NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet. Vigabatrin is an antiepileptic drug indicated for refractory complex partial seizures and used as an adjunctive therapy in patients who have inadequately responded to several alternative treatments.

Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)

Financials for Fiscal Year 2022 Ended March 31, 2022 will be released on June 29, 2022 NORTHVALE, NJ / ACCESSWIRE / June 23, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2022 year-end financial results on Wednesday, June 29, 2022. Elite's management will host a live conference call Thursday, June 30th at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022

NORTHVALE, NJ / ACCESSWIRE / May 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, today announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer (CFO), effective May 16, 2022, succeeding Marc Bregman. Mr. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations.

Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer

NORTHVALE, NJ / ACCESSWIRE / April 4, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that together with Elite's co-development partner, Praxgen Pharmaceuticals LLC, formerly SunGen Pharma LLC, ("Praxgen") received approval from the US Food and Drug Administration (FDA) for doxycycline hyclate 100 mg tablets. Doxycycline hyclate is an antibiotic that is used to treat a wide variety of bacterial infections.

Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline

Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q3 2022 Results - Earnings Call Transcript

Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2022 ended December 31, 2021 ("Third Quarter"). Consolidated revenues for the Third Quarter were $9.0 million, an increase of $2.9 million or 48% as compared to the corresponding period of the prior year, primarily due to stronger sales of Amphetamine IR Tablets and Amphetamine ER Capsules.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information

Financials for Third Quarter Fiscal Year 2022 Ended December 31, 2021 will be released February 14, 2022 NORTHVALE, NJ / ACCESSWIRE / February 9, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTC PINK:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2022 fiscal year will be released on Monday, February 14, 2022. Elite's management will host a live conference call Tuesday, February 15th at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financial Results on February 15, 2022

Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q2 2022 Results - Earnings Call Transcript

Conference Call Scheduled for Tuesday, November 16th at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / November 15, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2022 ended September 30, 2021 ("Second Quarter"). Consolidated revenues for the Second Quarter were $8.6 million, an increase of $1.2 million or 16% as compared to the corresponding period of the prior year, primarily due to stronger sales of Amphetamine IR Tablets and Amphetamine ER Capsules.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year Ended September 30, 2021 and Provides Conference Call Information

Financials for Second Quarter Fiscal Year 2022 Ended September 30, 2021 will be released November 15, 2021 NORTHVALE, NJ / ACCESSWIRE / November 9, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2022 fiscal year will be released on Monday, November 15, 2021. Elite's management will host a live conference call Tuesday, November 16 at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2022 Financial Results on November 16, 2021

Elite Pharmaceuticals, Inc. (ELTP) CEO Narsat Hakim on Q1 2022 Results - Earnings Call Transcript

Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / August 16, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company”) (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2022 ended June 30, 2021 ("First Quarter"). Total revenues for the three-month period ended June 30, 2021 decreased by $0.5 million or 6%, to $7.1 million, as compared to $7.5 million, for the corresponding period of the prior year, primarily due to timing of sales of Amphetamine IR Tablets and Amphetamine ER Capsules.

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 and Provides Conference Call Information

Financials for First Quarter Fiscal Year 2022 Ended June 30, 2021 will be released August 16, 2021 NORTHVALE, NJ / ACCESSWIRE / August 10, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2022 fiscal year will be released on Monday, August 16, 2021. Elite's management will host a live conference call Tuesday, August 17 at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2022 Financial Results on August 17, 2021

Elite Pharmaceuticals, Inc.'s (ELTP) CEO Nasrat Hakim on Q4 2021 Results - Earnings Call Transcript

Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 14, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company')(OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2021 ("Fiscal 2021"). Consolidated revenues for Fiscal 2021 were $25.4 million, an increase of $7.4 million or approximately 41% from the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conference Call Information

Financials for Fiscal Year Ended March 31, 2021 will be released June 14, 2021 NORTHVALE, NJ / ACCESSWIRE / June 8, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company') (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2021 year-end financial results on Monday, June 14, 2021. Elite's management will host a live conference call Tuesday, June 15 at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-End Financial Results on June 15, 2021

NORTHVALE, NJ / ACCESSWIRE / May 4, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that its distribution and marketing partner Prasco, LLC ("Prasco"), has launched Elite's generic Loxapine capsules. Elite entered a license, supply, and distribution agreement ("Agreement") with Prasco for Elite's Abbreviated New Drug Application (ANDA) for Loxapine Succinate capsules, 5 mg, 10 mg, 25 mg, and 50 mg ("Loxapine Capsules").

Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules

NORTHVALE, NJ / ACCESSWIRE / April 29, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, announced today that Marc Bregman, CPA, has been appointed as Chief Financial Officer (CFO), effective May 17, 2021. Mr. Bregman and will report to Elite's President and CEO, Nasrat Hakim.

Elite Pharmaceuticals, Inc. Names Marc Bregman as Chief Financial Officer

Elite Pharmaceuticals, Inc. (ELTP) CEO Nasrat Hakim on Q3 2021 Results - Earnings Call Transcript

NORTHVALE, NJ / ACCESSWIRE / January 5, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products, is pleased to announce the hiring of Dr. Jason M. LePree as Vice President of Scientific Affairs to oversee all technical facets of Elite's pharmaceutical and product development programs.

News for Elite Pharmaceuticals, Inc. Stock (ELTP)